ReviewAnnals of cardiothoracic surgery2020
Overcoming the transcatheter aortic valve replacement Achilles heel: coronary re-access.
Review in Annals of cardiothoracic surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 11 citations in OpenAlex.
- Coronary Revascularization in the Era of TAVR: Timing, Strategy, and Outcomes.Clinical Medicine Insights. Cardiology · 2025Review
- TAVR Interventions and Coronary Access: How to Prevent Coronary Occlusion.Life (Basel, Switzerland) · 2023Review
- Transaxillary Transcatheter Aortic Valve Replacement in a Patient With Previous Aortic Valve-Sparing Root Replacement: A Case Report.CJC open · 2023Article
- Bail out lithotripsy to treat delayed valve-in-valve TAVR-related coronary obstruction.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2023Article
- Coronary Artery Disease and Revascularization in Patients Undergoing Transcatheter Aortic Valve Replacement.Reviews in cardiovascular medicine · 2022Review
- Diagnostic Work-Up of the Aortic Patient: An Integrated Approach toward the Best Therapeutic Option.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcatheter aortic valve replacement (TAVR) is an alternative to surgical aortic valve replacement (SAVR) for the treatment of symptomatic severe aortic stenosis (AS). Coronary artery disease (CAD) is common in patients with severe AS. As the indications for TAVR extend to lower risk patients with longer life expectancy and as CAD is a progressive condition, coronary angiography will become increasingly common in patients who have had a previous TAVR. Coronary artery re-access after TAVR may be challenging but is possible in most cases. Commissural alignment of the prosthesis with the native coronary ostia plays an important role in successful coronary re-access. Coronary artery obstruction is a potentially devastating complication of TAVR, particularly in valve-in-valve procedures. In the present keynote lecture, we review techniques used to mitigate the risk of coronary obstruction, as well as catheter selection and strategies for selective coronary artery engagement for specific transcatheter aortic valve (TAV) bioprostheses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.